Association of Clinical Characteristics With Familial Hypercholesterolaemia Variants in a Lipid Clinic Setting: A Case-Control Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Familial hypercholesterolaemia (FH) variant positive subjects have over double the cardiovascular risk of low-density-lipoprotein-cholesterol (LDL-C) matched controls. It is desirable to optimise FH variant detection. Methods We identified 213 subjects with FH gene panel reports (LDLR, APOB, PCSK9, and APOE) based on total cholesterol >310 mg/dL; excluding triglycerides >400 mg/dL, cascade screening, and patients without pre-treatment LDL-C recorded. Demographic, clinical and lipid parameters were recorded. Results A 31/213 (14.6%) patients had pathogenic or likely pathogenic FH variants. 10/213 (4.7%) had variants of uncertain significance. Compared with patients without FH variants, patients with FH variants were younger (median age, 39 years vs. 48 years), had more tendon xanthomata (25.0% vs. 11.4%), greater proportion of first degree relatives with total cholesterol >95th percentile (40.6% vs. 16.5%), higher LDL-C (median, 271 mg/dL vs. 236 mg/dL), and lower triglycerides (median, 115 mg/dL vs. 159 mg/dL). The Besseling et al. model (c-statistic 0.798) improved FH variant discrimination over Friedewald LDL-C (c-statistic 0.724), however, Dutch Lipid Clinic Network Score (DLCNS) did not (c-statistic 0.665). Sampson LDL-C (c-statistic 0.734) had similar discrimination to Friedewald. Conclusion Although tendon xanthomata and first degree relatives with high total cholesterol >95th percentile were associated with FH variants, DLCNS or Simon Broome criteria did not improve FH detection over LDL-C. Sampson LDL-C did not significantly improve discrimination over Friedewald. Although lower triglycerides and younger age of presentation are positively associated with presence of FH variants, this information is not commonly used in FH detection algorithms apart from Besseling et al.
Abstract
Objective Familial hypercholesterolaemia (FH) variant positive subjects have over double the cardiovascular risk of low-density-lipoprotein-cholesterol (LDL-C) matched controls. It is desirable to optimise FH variant detection. Methods We identified 213 subjects with FH gene panel reports (LDLR, APOB, PCSK9, and APOE) based on total cholesterol >310 mg/dL; excluding triglycerides >400 mg/dL, cascade screening, and patients without pre-treatment LDL-C recorded. Demographic, clinical and lipid parameters were recorded. Results A 31/213 (14.6%) patients had pathogenic or likely pathogenic FH variants. 10/213 (4.7%) had variants of uncertain significance. Compared with patients without FH variants, patients with FH variants were younger (median age, 39 years vs. 48 years), had more tendon xanthomata (25.0% vs. 11.4%), greater proportion of first degree relatives with total cholesterol >95th percentile (40.6% vs. 16.5%), higher LDL-C (median, 271 mg/dL vs. 236 mg/dL), and lower triglycerides (median, 115 mg/dL vs. 159 mg/dL). The Besseling et al. model (c-statistic 0.798) improved FH variant discrimination over Friedewald LDL-C (c-statistic 0.724), however, Dutch Lipid Clinic Network Score (DLCNS) did not (c-statistic 0.665). Sampson LDL-C (c-statistic 0.734) had similar discrimination to Friedewald. Conclusion Although tendon xanthomata and first degree relatives with high total cholesterol >95th percentile were associated with FH variants, DLCNS or Simon Broome criteria did not improve FH detection over LDL-C. Sampson LDL-C did not significantly improve discrimination over Friedewald. Although lower triglycerides and younger age of presentation are positively associated with presence of FH variants, this information is not commonly used in FH detection algorithms apart from Besseling et al.
참고문헌 (14)
- Besseling J, "Selection of individuals for genetic testing for familial hypercholesterolaemia : development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia", Eur Heart J, 38, pp.565~573 (2017)
- Khera AV, "Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia", J Am Coll Cardiol, 67, pp.2578~2589 (2016)
- Huijgen R, "Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia : a cross-sectional study in 26, 406 individuals tested for genetic FH", Circ Cardiovasc Genet, 5, pp.354~359 (2012)
- Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998, "World Health Organization", World Health Organization, ~ (1999)
- Risk of fatal coronary heart disease in familial hypercholesterolaemia, "Scientific Steering Committee on behalf of the Simon Broome Register Group", BMJ, 303, pp.893~896 (1991)
- Mortality in treated heterozygous familial hypercholesterolaemia : implications for clinical management, "Scientific Steering Committee on behalf of the Simon Broome Register Group", Atherosclerosis, 142, pp.105~112 (1999)
- Shin DG, "Clinical features of familial hypercholesterolemia in Korea : predictors of pathogenic mutations and coronary artery disease-a study supported by the Korean Society of Lipidology and Atherosclerosis", Atherosclerosis, 243, pp.53~58 (2015)
- Clarke RE, "Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia", Heart, 99, pp.175~180 (2013)
- Nordestgaard BG, "Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population : guidance for clinicians to prevent coronary heart disease : consensus statement of the European Atherosclerosis Society", Eur Heart J, 34, pp.3478~3490 (2013)
- Sampson M, "A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and", or hypertriglyceridemia, 2020, pp.5, 540~548
- "Cardiovascular disease risk assessment and management for primary care" (2018)[URL]
- Janus ED, "Blood lipid levels in Christchurch blood donors", N Z Med J, 94, pp.114~115 (1981)
- Beheshti SO, "Worldwide prevalence of familial hypercholesterolemia : meta-analyses of 11 million subjects", J Am Coll Cardiol, 75, pp.2553~2566 (2020)
- Balder JW, "Lipid and lipoprotein reference values from 133, 450 Dutch Lifelines participants : age-and gender-specific baseline lipid values and percentiles", J Clin Lipidol, 11, pp.1055~1064 (2017)